Brief: Galectin Therapeutics Reports Positive Outcome Of Its Third Data And Safety Monitoring Board Meeting For Navigate
16/03/2023 12:28
March 16 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS INC - REPORTS POSITIVE OUTCOME OF
ITS
THIRD DATA AND SAFETY MONITORING BOARD MEETING FOR NAVIGATE
* GALECTIN THERAPEUTICS INC - INTERIM TOPLINE DATA FROM
PHASE 2B
PORTION OF NAVIGATE IS EXPECTED IN Q4 OF 2024
* GALECTIN THERAPEUTICS INC - BASED ON ITS DELIBERATION,
DSMB
CONCLUDED THAT NAVIGATE CAN CONTINUE AS DESIGNED, WITHOUT
MODIFICATIONS
Source text for Eikon: ID:nGNX8GpNbS
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study